Clinical Trials

5,018 enrolled 14 charts

Phase 2 Active not recruiting

Carcinoma, Intraductal, Noninfiltrating

NCT03179904 2026-02-24

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT04059484 2026-02-24

AMEERA-3

Phase 2 Terminated

367 enrolled 30 charts

Breast Cancer Metastatic

NCT01674140 2026-02-10

e3

1,939 enrolled 15 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00066690 2026-02-06

SOFT

3,066 enrolled 15 charts

Breast Neoplasms

NCT02115282 2025-12-18

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

608 enrolled 18 charts

Breast Neoplasms

NCT06086340 2025-11-18

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Completed

779 enrolled 9 charts

Breast Neoplasms, Neoplasm Metastasis

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

478 enrolled 16 charts 1 FDA

Breast Neoplasms

NCT02007512 2025-09-02

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

247 enrolled 27 charts

Breast Neoplasms

NCT04975308 2025-07-11

EMBER-3

874 enrolled 29 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT00253422 2025-06-04

SoFEA

698 enrolled 19 charts

Breast Neoplasms

NCT02040857 2025-04-29

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

162 enrolled 12 charts

Breast Neoplasms

NCT03219476 2025-04-29

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

37 enrolled 10 charts

Breast Neoplasms

NCT00265759 2025-04-23

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

622 enrolled 18 charts

Breast Neoplasms

NCT03691493 2025-02-17

ASPIRE

36 enrolled 17 charts

Breast Neoplasms

NCT01897441 2024-12-24

Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

Phase NA Terminated

31 enrolled 11 charts

Breast Neoplasms

NCT02028507 2024-09-25

PEARL

693 enrolled 40 charts

Breast Neoplasms

NCT01594216 2024-06-12

Ruxolitinib in Estrogen Receptor Positive Breast Cancer

25 enrolled 8 charts

Estrogen-receptor Positive Invasive Metastatic Breast Cancer

NCT04129216 2024-05-07

The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

30 enrolled 10 charts

Breast Neoplasms

NCT02648477 2024-03-19

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

30 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01814397 2024-02-07

Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients

Completed

50 enrolled 15 charts

Breast Neoplasms, Pain, Arthralgia

NCT03312738 2024-01-23

BOLERO-5

159 enrolled 25 charts

Breast Neoplasms

NCT02258451 2023-11-24

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

283 enrolled 22 charts

Breast Neoplasms

NCT00066573 2023-08-25

Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

7,576 enrolled 10 charts

Breast Neoplasms

NCT00083174 2023-08-25

ExCel

4,560 enrolled 16 charts

Breast Neoplasms

NCT02598557 2023-08-22

Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer

180 enrolled 46 charts

Breast Carcinoma In Situ, Breast Neoplasms

NCT01698918 2023-05-03

BOLERO-4

202 enrolled 19 charts

Breast Neoplasms

NCT02049957 2023-02-08

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

118 enrolled 30 charts

Breast Neoplasms

NCT02871791 2022-08-29

Palbociclib With Everolimus + Exemestane In BC

Phase 1/2 Completed

41 enrolled 12 charts

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

NCT03874325 2022-05-31

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Phase 2 Terminated

17 enrolled 10 charts

Breast Neoplasms

NCT01176916 2021-10-27

Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China

Phase 4 Completed

564 enrolled 13 charts

Breast Neoplasms

NCT01783444 2021-02-26

BOLERO-6

309 enrolled 19 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00810797 2020-10-19

Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer

36 enrolled 8 charts

Breast Neoplasms

NCT00905021 2020-07-24

EXTENT

Phase 1/2 Terminated

4 enrolled 6 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01627067 2020-06-19

Exemestane-RAD001-Metformin

Phase 2 Terminated

23 enrolled 7 charts

Breast Neoplasms

NCT03176238 2020-04-07

EVEREXES

235 enrolled 11 charts

Breast Neoplasms

NCT02291913 2020-02-17

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

48 enrolled 13 charts

Breast Neoplasms

NCT01720602 2020-01-07

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

Phase NA Completed

15 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01153672 2019-09-06

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy

Phase NA Completed

8 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT02983604 2019-08-07

GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

Phase 1/2 Terminated

14 enrolled 13 charts

Breast Neoplasms

NCT01743560 2019-07-18

4EVERUK

Phase 4 Completed

52 enrolled 16 charts

Breast Diseases, Breast Neoplasms, Neoplasms, Skin Diseases

NCT01597193 2019-05-08

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

Phase 1 Completed

101 enrolled 33 charts

Breast Neoplasms

NCT01381874 2019-04-11

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

297 enrolled 19 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01605396 2019-03-25

MK-8669-064

80 enrolled 13 charts

Breast Neoplasms

NCT01385280 2018-10-17

Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer

Phase NA Completed

13 enrolled 6 charts

Breast Neoplasms

NCT00201864 2018-07-26

Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer

40 enrolled 12 charts

Breast Neoplasms

NCT00728949 2018-06-06

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

93 enrolled 14 charts

Breast Neoplasms

NCT01484041 2018-02-09

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Phase 1/2 Terminated

12 enrolled 7 charts